PASSAGE BIO INC. - COMMON STOCK

U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

08 3 2021 07:00:00 提供 Nasdaq GlobeNewswire

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

03 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

Passage Bio to Participate in Upcoming March Investor Conferences

02 3 2021 16:01:00 提供 Nasdaq GlobeNewswire

Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021

24 2 2021 07:00:01 提供 Nasdaq GlobeNewswire

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

19 2 2021 07:00:00 提供 Nasdaq GlobeNewswire

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

08 2 2021 07:00:00 提供 Nasdaq GlobeNewswire

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

28 1 2021 07:00:01 提供 Nasdaq GlobeNewswire

Passage Bio Announces Pricing of Public Offering

21 1 2021 19:48:12 提供 Nasdaq GlobeNewswire

Passage Bio Announces Launch of Proposed Public Offering

19 1 2021 16:05:50 提供 Nasdaq GlobeNewswire

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

19 1 2021 07:00:00 提供 Nasdaq GlobeNewswire

Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021

11 1 2021 07:00:01 提供 Nasdaq GlobeNewswire

Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

04 1 2021 16:01:00 提供 Nasdaq GlobeNewswire

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

04 1 2021 07:00:00 提供 Nasdaq GlobeNewswire